Development of combined cellular and molecular target-directed therapies for glioblastoma

Material type: 文書・図像類

Author: Pyko, Ilyaほか

Publisher: -

Publication date: 2016-06-10

Material Format: Digital

Capacity, size, etc.: -

NDC: -

View All

Notes on use

Note (General)：: 金沢大学がん進展制御研究所膠芽腫は最悪性の脳原発希少がんであり、新しい治療法の開発が望まれている。最近、間葉系幹細胞が膠芽腫局所で抗腫瘍効果を示すことが報告された。我々はGSK3βのがん促進作用を発見し、その阻害による膠芽腫治療効果を実証してきた。近年、 GSK3β は間葉系幹細胞に抑制的に作用する...

Related materials as well as pre- and post-revision versions

https://kaken.nii.ac.jp/search/?qm=00731853

https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26893096/

https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26893096/26893096seika/

Search by Bookstore

Holdings of Libraries in Japan

This page shows libraries in Japan other than the National Diet Library that hold the material.

List of Cooperating Institutions and Databases

Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.

other

Kanazawa University Repository for Academic Resources
Digital
You can check the holdings of institutions and databases with which Institutional Repositories DataBase(IRDB)(Institutional Repository) is linked at the site of Institutional Repositories DataBase(IRDB)(Institutional Repository).
Kanazawa University Repository for Academic Resources

Search by Bookstore

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type: 文書・図像類
Title: Development of combined cellular and molecular target-directed therapies for glioblastoma
Author/Editor: Pyko, Ilya
ピコ, イリア
Author Heading: Pyko, Ilya
ピコ, イリア
Publication Date: 2016-06-10
Publication Date (W3CDTF): 2016-06-10
Periodical title: 平成27(2015)年度科学研究費補助金研究活動スタート支援研究成果報告書 = 2015 Fiscal Year Final Research Report
No. or year of volume/issue: 2014-08-29 - 2016-03-31
Volume: 2014-08-29 - 2016-03-31
Pages: 4p.-
Text Language Code: jpn
Subject Heading: glioblastoma
temozolomide
mesenchymal stem cells
GSK 3β
Target Audience: 一般
Note (General): 金沢大学がん進展制御研究所
膠芽腫は最悪性の脳原発希少がんであり、新しい治療法の開発が望まれている。最近、間葉系幹細胞が膠芽腫局所で抗腫瘍効果を示すことが報告された。我々はGSK3βのがん促進作用を発見し、その阻害による膠芽腫治療効果を実証してきた。近年、 GSK3β は間葉系幹細胞に抑制的に作用することが報告されている。そこで、膠芽腫細胞と動物モデルを対象に、 GSK3β阻害剤と間葉系幹細胞移植の治療効果を調べた。その結果、膠芽腫の幹細胞性腫瘍細胞に対する間葉系幹細胞の治療的作用はGSK3β阻害剤の併用により増強された。本研究の結果は、間葉系幹細胞移植とGSK3β阻害剤の併用による新たな膠芽腫治療法の開発に有用である。
We investigated whether mesenchymal stem cells (MSCs) transplantation benefits to treatment of glioblastoma (GBM) by enhancing anti-tumor effect in combination with GSK3β inhibitors and temozolomide (TMZ). Our experiments showed that transplantation of MSCs and GSK3β inhibition synergizes for treatment of experimental GBM and that MSCs co-cultured with GBM cells participate in regulation of GBM stemness similar to that observed under GSK3β inhibition. We also examined the interaction between patient-derived GBM stem-like cells and adipose tissue-derived MSCs in the presence and absence of GSK3β inhibition and TMZ and its influence on GBM stemness. We found that the interaction of MSCs with GBM stem-like cells is enhanced by a combined treatment by GSK3β inhibitor. These observations encouraged us to continue investigation of the biological mechanisms by which MSCs regulate GBM stemness under the control by GSK3β addressing the role of cell-to-cell interactions and local signals.
研究課題/領域番号:26893096, 研究期間(年度):2014-08-29 - 2016-03-31
DOI: 10.24517/00055472
Access Restrictions: 限定公開
Related Material: https://kaken.nii.ac.jp/search/?qm=00731853
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26893096/
https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26893096/26893096seika/
Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）
https://irdb.nii.ac.jp
Original Data Provider (Database): 金沢大学 : 金沢大学学術情報リポジトリKURA